Fulltext

Defining Responses to Therapy and Study Outcomes in Clinical Trials of Invasive Fungal Diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer Consensus Criteria

Segal, Brahm H. ; Herbrecht, Raoul ; Stevens, David A. ; Ostrosky-Zeichner, Luis ; Sobel, Jack ; Viscoli, Claudio ; Walsh, Thomas J. ; Maertens, Johan ; Patterson, Thomas F. ; Perfect, John R. ; Dupont, Bertrand ; Wingard, John R. ; Calandra, Thierry ; Kauffman, Carol A. ; Graybill, John R. ; Baden, Lindsey R. ; Pappas, Peter G. ; Bennett, John E. ; Kontoyiannis, Dimitrios P. ; Cordonnier, Catherine ; Viviani, Maria Anna ; Bille, Jacques ; Almyroudis, Nikolaos G. ; Wheat, L. Joseph ; Graninger, Wolfgang ; Bow, Eric J. ; Holland, Steven M. ; Kullberg, Bart-Jan ; Dismukes, William E. ; De Pauw, Ben E.

In: Clinical Infectious Diseases, 2008, vol. 47, no. 5, p. 674-683

Ajouter à la liste personnelle
    Titre
    • Defining Responses to Therapy and Study Outcomes in Clinical Trials of Invasive Fungal Diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer Consensus Criteria
    Auteur
    • Segal, Brahm H.. Department of Medicine, Roswell Park Cancer Institute, Buffalo, New York
    • Herbrecht, Raoul. Department of Hematology and Oncology, Hospital de Hautepierre, Strasbourg
    • Stevens, David A.. Santa Clara Valley Medical Center, San Jose
    • Ostrosky-Zeichner, Luis. University of Texas Health Science Center at Houston, Durham, North Carolina
    • Sobel, Jack. Wayne State University School of Medicine, Detroit, Michigan
    • Viscoli, Claudio. University of Genova, Milan
    • Walsh, Thomas J.. Pediatric Oncology Branch, National Cancer Institute, Durham, North Carolina
    • Maertens, Johan. Acute Leukemia and Hematopoietic Stem Cell Transplant Unit, Department of Hematology, University Hospital Gaithuisberg, Leuven, Belgium
    • Patterson, Thomas F.. Department of Medicine, University of Texas Health Science Center, San Antonio, Durham, North Carolina
    • Perfect, John R.. Duke University Medical Center, Durham, North Carolina
    • Dupont, Bertrand. Maladies Infectieuses et Tropicales, Hospital Necker, Paris
    • Wingard, John R.. University of Florida College of Medicine, Gainsville
    • Calandra, Thierry. Infectious Disease Service/Department of Medicine, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland
    • Kauffman, Carol A.. University of Michigan, Veterans Administration Ann Arbor Healthcare System, Ann Arbor, Durham, North Carolina
    • Graybill, John R.. Department of Medicine, University of Texas Health Science Center, San Antonio, Durham, North Carolina
    • Baden, Lindsey R.. Division of Infectious Diseases, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Cambridge, Massachusetts
    • Pappas, Peter G.. Department of Medicine, University of Alabama at Birmingham, Durham, North Carolina
    • Bennett, John E.. Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, Maryland
    • Kontoyiannis, Dimitrios P.. The University of Texas M. D. Anderson Cancer Center, Durham, North Carolina
    • Cordonnier, Catherine. Henri Mondor Hospital APHP and Paris 12 University, Creteil, France
    • Viviani, Maria Anna. Universita degli Studi, Department of Public Health, Microbiology, and Virology, Section of Public Health, Milan
    • Bille, Jacques. Institute of Microbiology University Hospital, Nijmegen, The Netherlands
    • Almyroudis, Nikolaos G.. Department of Medicine, Roswell Park Cancer Institute, Buffalo, New York
    • Wheat, L. Joseph. MiraVista Diagnostics/MiraBella Technologies, Indianapolis, Indiana
    • Graninger, Wolfgang. Medical University of Vienna, Creteil, France
    • Bow, Eric J.. CancerCare Manitoba, University of Manitoba, Winnipeg, Manitoba, Canada
    • Holland, Steven M.. Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, Maryland
    • Kullberg, Bart-Jan. Department of Medicine, Nijmegen University Medical Center, Winnipeg, Manitoba, Canada
    • Dismukes, William E.. Department of Medicine, University of Alabama at Birmingham, Durham, North Carolina
    • De Pauw, Ben E.. University Medical Center St. Raboud, Winnipeg, Manitoba, Canada
    Type de document
    • Postprint
    Langue
    • Anglais
    Publié dans
    • Clinical Infectious Diseases, 2008, vol. 47, no. 5, p. 674-683. The University of Chicago Press
    Autre version électronique
    Classification
    • Santé
    Identifiant OAI-PMH
    • oai:doc.rero.ch:301179
    Summary
    Invasive fungal diseases (IFDs) have become major causes of morbidity and mortality among highly immunocompromised patients. Authoritative consensus criteria to diagnose IFD have been useful in establishing eligibility criteria for antifungal trials. There is an important need for generation of consensus definitions of outcomes of IFD that will form a standard for evaluating treatment success and failure in clinical trials. Therefore, an expert international panel consisting of the Mycoses Study Group and the European Organization for Research and Treatment of Cancer was convened to propose guidelines for assessing treatment responses in clinical trials of IFDs and for defining study outcomes. Major fungal diseases that are discussed include invasive disease due to Candida species, Aspergillus species and other molds, Cryptococcus neoformans, Histoplasma capsulatum, and Coccidioides immitis. We also discuss potential pitfalls in assessing outcome, such as conflicting clinical, radiological, and/or mycological data and gaps in knowledge